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Allogeneic hematopoietic cell transplantation (HCT) is the only treatment able to prevent progressive
neurodegenerative disease in a selected group of mucopolysaccharidosis (MPS) disorders. However, its use
was historically limited by the high risk of graft failure and transplantation-related morbidity and mortality.
Therefore, since 2005 new international HCT guidelines for MPS disorders were proposed. The survival and
graft outcomes of MPS patients receiving HCT according to these guidelines in 2 European centers of expertise
were evaluated. Two consecutive conditioning regimens were used, busulfan/cyclophosphamide or
ﬂudarabine/busulfan-based, both with exposure-targeted i.v. busulfan. A noncarrier matched sibling donor
(MSD), matched unrelated cord blood (UCB), or matched unrelated donor (MUD) were considered to be
preferred donors. If not available, a mismatched UCB donor was used. Participants were 62 MPS patients (56
MPS type IeHurler, 2 MPS type II, 2 MPS type III, and 2 MPS type VI) receiving HCT at median age 13.5 months
(range, 3 to 44). Forty-one patients received a UCB donor, 17 MSD, and 4 MUD. High overall survival (95.2%)
and event-free survival (90.3%) were achieved with only low toxicity: 13.3% acute graft-versus-host disease
aGVHD) grades II to IV and 14.8% chronic GVHD (1.9% extensive). A mismatched donor predicted for lower
event-free survival (P ¼ .04). A higher age at HCT was a predictor for both aGVHD (P ¼ .001) and chronic GVHD
(P ¼ .01). The use of a mismatched donor was a predictor for aGVHD (P ¼ .01). Higher rates of full-donor
chimerism were achieved in successfully transplanted UCB recipients compared with MSD/MUD (P ¼ .002).
If complying with the international HCT guidelines, HCT in MPS patients results in high safety and efﬁcacy.
This allows extension of HCT to more attenuated MPS types. Because a younger age at HCT is associated with
reduction of HCT-related toxicity, newborn screening may further increase safety.
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ty for Blood and Marrow Transplantation.[1]. Allogeneic hematopoietic cell transplantation (HCT) is the
only treatment option able to prevent progressive neurode-
generative disease in a selected group of MPS disorders [2].
However, its use is limited by a high risk of graft failure and
transplantation-related morbidity and mortality [3].
In 2005, the European group for Blood and Marrow
Transplantation developed transplantation guidelines for
HCT in MPS patients based on a European predictor analysis
study [3]. In 2012, the busulfan-based conditioning regimen
was slightly modiﬁed by replacing cyclophosphamide with
ﬂudarabine, because studies demonstrated similar efﬁcacy
Table 1
Baseline Characteristics
n (%) Median
(range)
Number of patients 62
Gender, males 37 (59.7)
Diagnosis, MPS type
IeHurler*
56 (90.3)
Age at HCT,y mo 13.5 (3-44)
Follow-up post-HCT, mo 36.0 (1-93)
Conditioning regimen, BuCy 29 (46.8)
Donor, UCB/UBM or
UPBSC/MSD
41/4/17 (66.1/6.5/27.4)
HLA disparity, matchedz 44 (71.0)
TNCs infused, 107/kg
CB 9.8 (1-102)
BM 69.0 (15-218)
PBSCs 109.5 (76-170)
CD34þ cells infused, 105/kg
CB 4.0 (.5-52)
BM 103.0 (12-564)
PBSCs 122.5 (82-426)
UBM/UPBSC indicates unrelated BM/unrelated PBSCs; MSD, matched sibling
donor; TNCs, total nucleated cells; CB, cord blood.
* Other MPS types included MPS type IIeHunter (n ¼ 2), MPS type
IIIeSanﬁlippo (n ¼ 2), and MPS type VIeMaroteaux-Lamy (n ¼ 2).
y 12.0 months (range, 3-36) in MPS type IeHurler patients.
z n¼ 28 UCB, n¼ 4 UBM/UPBSCs, n¼ 16MSD; regarding UCB donors: n¼
24 matched (6/6), n ¼ 17 mismatched (n ¼ 11 5/6, n ¼ 6 4/6).
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evaluated the survival and graft outcomes of HCT in MPS
patients, complying with the international guidelines, in 2
centers performing the highest numbers of HCTs in MPS
patients in Europe.
METHODS
Patients
MPS patients consecutively treated at the University Medical Center
Utrecht (UMCU) or the Royal Manchester Children’s Hospital (RMCH) ac-
cording to the European group for Blood and Marrow Transplantation
guidelines for HCT in MPS patients (www.ebmt.org) were included in the
study. The study was approved by the institutional review boards of the 2
centers. Written informed consent was obtained from the parents or legal
guardians of the patients.
Conditioning Regimens and Donor Hierarchy
Busulfan þ cyclophosphamide (BuCy) was the conditioning regimen
used from December 2004 to January 2009. Busulfan was administered
intravenously for 4 consecutive days using dose targeting based on thera-
peutic drug monitoring, as previously described [4]. Cyclophosphamide was
dosed at 50 mg/kg for 4 days and administered at least 24 hours after
busulfan. At UMCU, Thymoglobulin (Sanoﬁ, Cambridge, MA) 10 mg/kg (cu-
mulative dose over 4 days) was administered over 4 days to all recipients of
unrelated donor grafts. At RMCH, Thymoglobulin 10mg/kg (cumulative dose
over 4 days) was used in all unrelated cord blood (UCB) transplants, whereas
alemtuzumab was given as serotherapy to recipients of both unrelated
(1 mg/kg over 5 days) and related (0.3 mg/kg over 3 days) bone marrow
(BM) or peripheral blood stem cell (PBSC) donor grafts.
Fludarabineþ busulfan (FluBu) was the conditioning regimen used from
January 2009 to March 2014. Fludarabine 40 mg/m2 was administered
intravenously during 4 consecutive days, 1 hour before busulfan infusion.
Busulfan was administered intravenously for 4 days, using dose targeting
based on therapeutic drug monitoring, as previously described [4]. Sero-
therapy was similar to the previous period.
For donor hierarchy, a noncarrier matched sibling donor, identical UCB
(6/6 on intermediate resolution), or identical matched unrelated donor (10/
10 on high-resolution typing) was used. If these donors were not available,
preferably a mismatched UCB donor was used.
Supportive Care
Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine
A in all patients. At UMCU, methotrexate was added on days þ1, þ3, and þ6
after HCT in recipients of a BM transplant. In recipients of a UCB donor,
prednisolone (1 mg/kg/day until day þ28) was added after HCT. Antimi-
crobial prophylaxis was standard for all patients and consisted of cipro-
ﬂoxacin, ﬂuconazole/itraconazole, and acyclovir. All MPS type IeHurler
patients received enzyme replacement therapy peritransplant, 100 U/kg
weekly, typically beginning at least 6 weeks before transplant and
continuing until either conditioning (UMCU) or engraftment was estab-
lished (RMCH).
Primary and Secondary Endpoints and Deﬁnitions
Overall survival (OS) was deﬁned as survival from HCT to last contact or
death. Event-free survival (EFS) was deﬁned as survival from HCT to last
contact, death, autologous reconstitution (<10% donor-derived engraft-
ment), or graft-failure (lack of neutrophil recovery or transient engraftment
of donor cells after HCT and/or requirement for a second HCT).
Secondary endpoints were neutrophil engraftment (ﬁrst day of
achieving a neutrophil count > .5  109/L for 3 consecutive days) and
platelet engraftment (platelet count > 50  109/L for 7 consecutive days).
Grades II to IV acute GVHD (aGVHD) was graded according to published
criteria [5], and both limited and extensive chronic GVHD (cGVHD) were
graded according to standard criteria and evaluated in patients who sur-
vived at least 100 days with sustained engraftment [6]. Veno-occlusive
disease, deﬁned according to Bearman [7], and viral reactivation of cyto-
megalovirus, adenovirus, and Epstein-Barr virus with a viral load > 1000
cm/mL were recorded. A donor chimerism > 95% was considered as full
donor. An enzyme level above the local lower reference limit was considered
normal. Urinary glycosaminoglycan excretion below the local upper refer-
ence limit was considered normal.
Statistical Analysis
For predictor analysis, we selected patient (gender, diagnosis, age at
HCT) and HCT-related (HCT center, conditioning regimen, donor type, HLA
disparity, total nucleated cells infused) factors. The association between
these factors and the primary and secondary endpoints were analyzedusing Cox proportional hazards regression analysis. Univariate predictors
of endpoints with P < .10 were selected for multivariate analysis. Pre-
dictors with P < .05 in multivariate analysis were considered statistically
signiﬁcant. Kaplan-Meier curves were used to depict outcome probabili-
ties. Statistical analysis was performed using SPSS version 20.0 (IBM,
Armonk, NY).
RESULTS
Patient Characteristics
Sixty-two MPS patients were included: 56 MPS type
IeHurler, 2 MPS type IIeHunter, 2 MPS type IIIeSanﬁlippo,
and 2 MPS type VIeMaroteaux-Lamy. Twenty-nine received
a BuCy conditioning regimen and 33 a FluBu conditioning
regimen. Median age at HCT was 13.5 months (range, 3 to
44). Forty-one patients received a UCB transplant and 21 an
unrelated or matched sibling BM or PBSC transplant. Median
follow-up was 36 months post-HCT (range, 1 to 93). All
baseline characteristics are shown in Table 1.
OS and EFS
The OS ratewas 95.2%, whereas EFSwas achieved in 90.3%
of patients (Table 2, Figure 1). Causes of death were idio-
pathic pneumonia (n ¼ 2) and cGVHD (n ¼ 1). All 3 patients
with graft failure received a second HCT with subsequent
achievement of donor engraftment and were alive at latest
follow-up time point. A mismatched donor predicted for
lower EFS (hazard ratio, .176; P ¼ .04; Figure 2).
Secondary Endpoints
Neutrophil and platelet engraftment were achieved after
amedian of 16.5 (range,10 to 39) and 31 days (range, 0 to 89),
respectively. A higher infused total nucleated cell dose pre-
dicted for higher neutrophil (P ¼ .04) engraftment rates in
BM recipients. The probability of aGVHD grades II to IV was
13.3%, whereas 14.8% of the patients were diagnosed with
cGVHD (1.9% extensive). A higher age at HCT was a predictor
for both aGVHD (P ¼ .001) and cGVHD (P ¼ .01). The use of a
mismatched donor was a predictor for aGVHD (P ¼ .01). The
incidences of veno-occlusive disease and viral reactivations
Table 2
Primary and Secondary Endpoints
n (%)
Total CB BM/PBSCs
Number of patients 62 41 21
Primary endpoints
OS* 59 (95.2) 39 (95.1) 20 (95.2)
EFSy 56 (90.3) 36 (87.8) 20 (95.2)
n (%) Median (range)
Total CB BM/PBSCs Total CB BM/PBSCs
Secondary endpoints
Neutrophil engraftment, days post-HCT 60 (96.8) 39 (95.1) 21 (100.0) 16.5 (10-39) 17.0 (11-39) 16.0 (10-22)
Platelet engraftment, days post-HCT 57 (93.4) 36 (90.0) 21 (100.0) 31.0 (0-89) 31.5 (16-89) 25.0 (0-55)
aGVHD (grades II-IV), days post-HCT 8 (13.3) 6 (15.4) 2 (9.5) 40.5 (19-71) 49.0 (19-71) 34.0 (33-35)
cGVHD (all grades), mo post-HCTz 8 (14.8) 5 (15.2) 3 (14.3) 5.0 (3.3-15.1) 5.9 (3.3-15.1) 5.0 (3.3-7.5)
Veno-occlusive disease 0 (0) 0 (0) 0 (0)
CMV reactivation, days post-HCT 5 (8.1) 4 (9.8) 1 (4.8) 13.0 (4-59) 13.0 (4-59) 12.0
Adenovirus reactivation, days post-HCT 9 (14.5) 5 (12.2) 4 (19.0) 16.0 (1-76) 18.0 (6-76) 11.0 (1-25)
EBV reactivation, days post-HCT 5 (8.1) 3 (7.3) 2 (9.5) 41.0 (40-130) 21.0 (40-41) 93.5 (57-130)
Full-donor chimerism 30 (88.2x) 23 (100x) 7 (63.6x)
Normal enzyme level 39 (95.1x) 26 (96.3x) 13 (92.9x)
Normal urinary GAG excretion 47 (100x) 29 (100x) 18 (100x)
CMV indicates cytomegalovirus; EBV, Epstein-Barr virus; GAG, glycosaminoglycan.
* n ¼ 3 death, at 2, 3, and 37 months post-HCT.
y n ¼ 3 graft failure, at .7, .8, and 4.3 months post-HCT, all receiving a second HCT with subsequent donor engraftment.
z n ¼ 1 extensive cGVHD.
x Of alive and engrafted patients with testing  12 months post-HCT.
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enzyme levels, and normalized urinary glycosaminoglycan
excretion after a follow-up of at least 12 months were found
in 88.2%, 95.1%, and 100%, respectively, of patients with
successful donor engraftment. Higher rates of full-donor
chimerism were achieved in successfully transplanted UCB
recipients, compared with recipients of BM/PBSCs (100%
versus 63.6%, P ¼ .002).
Signiﬁcant results of multivariate predictor analysis are
shown in Table 3. No differences were found between using a
BuCy and FluBu conditioning regimen in any endpoint or
between the 2 HCT centers.DISCUSSION
In this study we clearly showedwhen complying with the
international HCT guidelines, HCT in MPS patients results in
remarkably low toxicity and high engrafted survival rates.
This is signiﬁcantly improved compared with the 45 MPS
type IeHurler patients transplanted between 1994 and 2004Figure 1. Overall survival and event-free survival.in the same 2 HCT centers (OS 77.8%, EFS 40.0%;
Supplemental Figure 1). The results of this study hereby
conﬁrm the previously reported observations of higher sur-
vival and engraftment rates concerning HCT in MPS type
IeHurler patients using a fully ablative conditioning regimen
with busulfan therapeutic drug monitoring and strict donor
hierarchy [3,8,9].
The incidence of grades II to IV aGVHD was lower
compared with that observed in similar patient cohorts [8-
10], presumably because of the relatively low number of
donorerecipient HLA mismatching in our study population
and the use of UCB in most patients. Improved matching
possibilities might further improve this endpoint. The overall
cGVHD incidence was comparable with or lower than pre-
vious studies, with only 1 patient developing extensive
cGVHD [8-10]. Because a younger age at HCT is associated
with reduced HCT-related toxicity, newborn screening and
subsequent timely HCT might increase safety even further.
Although extensive results on survival and graft outcome inFigure 2. Inﬂuence of HLA matching on event-free survival.
Table 3
Multivariate Predictor Analysis: Signiﬁcant Predictors
Predictor HR 95% CI P
Primary endpoint
EFS HLA disparity
(mismatched)
.18 .03-.97 .04
Secondary endpoints
Neutrophil engraftment* TNCs infused
(107/kg)y
1.01 1.00-1.02 .04
aGVHD (grades II-IV) Age at HCT, moy 1.13 1.05-1.21 .001
HLA disparity
(mismatched)
9.38 1.70-51.83 .01
cGVHD (all grades) Age at HCT, moy 1.08 1.02-1.15 .01
CMV reactivation Age at HCT, moy 1.09 1.01-1.18 .02
Full-donor chimerism Source (UCB) 9.50 2.21-40.86 .002
HR indicates hazard ratio; CI, conﬁdence interval.
* Only in bone marrow recipients.
y Continuous variable.
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lacking, the results in patients with severe combined im-
munodeﬁciency receiving HCT at 3.5 months of age or
younger are hopeful [11]. Median age at HCT of the MPS type
IeHurler patients in this study was 12.0 months (range, 3 to
36). This is considerably lower compared with the median
age of 16.7 months described in a study concerning HCT
performed in similar patients between 1995 and 2007 [9].
A younger age at HCT is also important for the long-term
prognosis of MPS type IeHurler syndrome patients,
including their neurodevelopment [12].
To achieve maximal engrafted survival rates, a noncarrier
matched sibling, fullymatched UCB, or adult unrelated donor
remains the highly preferred donor in MPS patients. A mis-
matched UCB donor is a suitable alternative option, also
resulting in high engrafted OS (94.1%). The number of events
was too low to analyze the effect of the degree of mismatch
on EFS. In line with previous studies, the use of a UCB donor
was associated with higher levels of full-donor chimerism
compared with BM/PBSCs [9]. Although high rates of normal
enzyme levels were achieved in both UCB and BM/PBSC re-
cipients in this study, mixed chimerism remains a risk for
lower enzyme levels in the long term, as seen in larger
studies [9]. Normal enzyme levels post-HCT appeared to be
highly important for the long-term prognosis of MPS type
IeHurler syndrome patients [12]. Furthermore, UCB donor
grafts are readily accessible, enabling the reduction of the
time from donor search to transplant and thereby the age at
HCT, which was another signiﬁcant predictor for superior
long-term outcomes [12]. Taken together, in our view fully
matched UCB grafts could therefore be considered the most
attractive source for HCT in MPS patients even when a
noncarrier matched sibling donor is available.
The observed high engrafted survival rates after HCT with
low toxicity in MPS patients will enable the extension of HCT
indication to the more “attenuated” MPS (sub)types, for
example, MPS type IeHurler-Scheie. The potential applica-
tion of HCT to attenuated MPS patients, many of whom are
currently treated with enzyme replacement therapy, is
further supported by the fact that enzyme replacement
therapy may initiate antibody formation, which is not
observed after HCT [13]. In addition, it was previously shownthat HCT is associated with superior metabolic correction
compared with enzyme replacement therapy [14].
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